Bai Xiaosong - Executive Director and Chairman
Mr. Bai Xiaosong, was appointed as an Executive Director of the Company in January 2022, and was appointed as the chairman of the board and the chairman of the nomination committee of the Company in August 2024. Mr. Bai currently serves as a director of CR Sanjiu and CR Double-Crane. Mr. Bai served as the chairman and a director of Dong-E-E-Jiao, and a vice president of CR Sanjiu from June 2021 to December 2021. He served as an assistant general manager of China Resources Snow Breweries (China) Co., Ltd. (华润雪花啤酒(中国)有限公司) (“CR Snow Breweries”) from March 2016 to October 2018 and served as a deputy general manager of CR Snow Breweries from October 2018 to June 2021. He also served as an associate president of CR Double-Crane, a human resources and development controller and a deputy general manager of China Resources Shenyang Sanyo Compressor Co., Ltd. (沈阳华润三洋压缩机有限公司), a senior analyst and a sales director of CR Holdings. Mr. Bai holds a bachelor’s degree in Engineering (Petroleum Processing) from Fushun Petroleum Institute, Department of Petrochemical Engineering and a master’s degree of Economics in Finance from Peking University, School of Economics.
Mr. Bai Xiaosong, was appointed as an Executive Director of the Company in January 2022, and was appointed as the chairman of the board and the chairman of the nomination committee of the Company in August 2024. Mr. Bai currently serves as a director of CR Sanjiu and CR Double-Crane. Mr. Bai served as the chairman and a director of Dong-E-E-Jiao, and a vice president of CR Sanjiu from June 2021 to December 2021. He served as an assistant general manager of China Resources Snow Breweries (China) Co., Ltd. (华润雪花啤酒(中国)有限公司) (“CR Snow Breweries”) from March 2016 to October 2018 and served as a deputy general manager of CR Snow Breweries from October 2018 to June 2021. He also served as an associate president of CR Double-Crane, a human resources and development controller and a deputy general manager of China Resources Shenyang Sanyo Compressor Co., Ltd. (沈阳华润三洋压缩机有限公司), a senior analyst and a sales director of CR Holdings. Mr. Bai holds a bachelor’s degree in Engineering (Petroleum Processing) from Fushun Petroleum Institute, Department of Petrochemical Engineering and a master’s degree of Economics in Finance from Peking University, School of Economics.
Cheng Jie - Executive Director and President
Mr. Cheng Jie, has been appointed as an executive Director, the President and a member of each of the Executive Committee and Corporate Governance Committee on 26 August 2025. He is currently the director of certain subsidiaries of the Company. He has been serving as the chairman of Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (‘Dong-E-E-Jiao’, a subsidiary of the Company, the shares of which are listed on the Shenzhen Stock Exchange (stock code: 000423)) since September 2024. He served as the 999 Ganmaoling product manager and product director, OTC sales and marketing director, deputy general manager of marketing center, and general manager of professional brands division of China Resources Sanjiu Medical & Pharmaceutical Company Limited (華潤三九醫藥股份有限公司) (a subsidiary of the Company, the shares of which are listed on the Shenzhen Stock Exchange (stock code: 000999)) from July 2003 to January 2022. He has also served as the executive director of Aino (China) Pharmaceutical Co., Ltd. (澳諾(中國)製藥有限公司) from December 2019 to January 2022, director and general manager of Sanjiu Sanofi (Shenzhen) Health Industry Co., Ltd (三九賽諾菲(深圳)健康產業有限公司) from January 2017 to January 2022, and the president of Dong-E-E-Jiao from January 2022 to September 2024. Mr. Cheng was awarded the title of National Model Worker in 2025, Taishan Industrial Leadership Talent (Business Management Category) in 2023, Shandong Province Model Worker in 2023, etc. Mr. Cheng graduated from Shenyang Pharmaceutical University in the PRC in July 2003 with a Bachelor’s degree in Science. He holds the title of senior engineer.
Mr. Cheng Jie, has been appointed as an executive Director, the President and a member of each of the Executive Committee and Corporate Governance Committee on 26 August 2025. He is currently the director of certain subsidiaries of the Company. He has been serving as the chairman of Dong-E-E-Jiao Company Limited (東阿阿膠股份有限公司) (‘Dong-E-E-Jiao’, a subsidiary of the Company, the shares of which are listed on the Shenzhen Stock Exchange (stock code: 000423)) since September 2024. He served as the 999 Ganmaoling product manager and product director, OTC sales and marketing director, deputy general manager of marketing center, and general manager of professional brands division of China Resources Sanjiu Medical & Pharmaceutical Company Limited (華潤三九醫藥股份有限公司) (a subsidiary of the Company, the shares of which are listed on the Shenzhen Stock Exchange (stock code: 000999)) from July 2003 to January 2022. He has also served as the executive director of Aino (China) Pharmaceutical Co., Ltd. (澳諾(中國)製藥有限公司) from December 2019 to January 2022, director and general manager of Sanjiu Sanofi (Shenzhen) Health Industry Co., Ltd (三九賽諾菲(深圳)健康產業有限公司) from January 2017 to January 2022, and the president of Dong-E-E-Jiao from January 2022 to September 2024. Mr. Cheng was awarded the title of National Model Worker in 2025, Taishan Industrial Leadership Talent (Business Management Category) in 2023, Shandong Province Model Worker in 2023, etc. Mr. Cheng graduated from Shenyang Pharmaceutical University in the PRC in July 2003 with a Bachelor’s degree in Science. He holds the title of senior engineer.
Liu Changan - Executive Director
Mr. Liu Changan, has been appointed as an executive Director and a member of the Executive Committee on 18 September 2025. He has been a director of China Resources Pharmaceutical Holdings Company Limited, a subsidiary of the Company, since October 2024. Mr. Liu served in the Agricultural Committee and Agricultural Bureau of the Beijing Municipal Party Committee from January 2023 to July 2023. Mr. Liu graduated from the National Defense University of the People’s Liberation Army in January 2004 with a Master’s degree.
Mr. Liu Changan, has been appointed as an executive Director and a member of the Executive Committee on 18 September 2025. He has been a director of China Resources Pharmaceutical Holdings Company Limited, a subsidiary of the Company, since October 2024. Mr. Liu served in the Agricultural Committee and Agricultural Bureau of the Beijing Municipal Party Committee from January 2023 to July 2023. Mr. Liu graduated from the National Defense University of the People’s Liberation Army in January 2004 with a Master’s degree.
Guo Wei - Non-executive Director
Mdm. Guo Wei, was appointed as a non-executive Director in February 2023 and has been appointed as a member of the Audit Committee on 27 December 2023. She is currently serving as a designated external director of the business unit of CR Holdings, and was appointed as a non-executive director of China Resources Beer (Holdings) Company Limited (listed on the Stock Exchange, stock code: 291) in September 2023. Mdm. Guo was a non-executive director from May 2019 to September 2021, and was an assistant director (currently known as assistant general manager) and a deputy financial director of the Finance Department of CR Holdings from August 2013 to April 2022. She was a director of CR Double-Crane from December 2015 to September 2021 and a director of CR Sanjiu from April 2018 to September 2021. Mdm. Guo holds a bachelor’s degree in economics from University of International Business and Economics and a master’s degree in law from Peking University.
Mdm. Guo Wei, was appointed as a non-executive Director in February 2023 and has been appointed as a member of the Audit Committee on 27 December 2023. She is currently serving as a designated external director of the business unit of CR Holdings, and was appointed as a non-executive director of China Resources Beer (Holdings) Company Limited (listed on the Stock Exchange, stock code: 291) in September 2023. Mdm. Guo was a non-executive director from May 2019 to September 2021, and was an assistant director (currently known as assistant general manager) and a deputy financial director of the Finance Department of CR Holdings from August 2013 to April 2022. She was a director of CR Double-Crane from December 2015 to September 2021 and a director of CR Sanjiu from April 2018 to September 2021. Mdm. Guo holds a bachelor’s degree in economics from University of International Business and Economics and a master’s degree in law from Peking University.
Sun Yongqiang - Non-executive Director
Mr. Sun Yongqiang，was appointed as a non-executive Director and a member of the Remuneration Committee on 27 December 2023. He currently serves as a designated external director of business units of China Resources (Holdings) Company Limited. Mr. Sun joined China Resources Group in March 2001. From 2011 to 2023, he successively served as vice president, chief human resources officer and human resources director of China Resources Land Limited (“CR Land”, which is listed on the Main Board of the Stock Exchange, Stock Code: 1109), and also served as General manager and deputy general manager of China Resources Land (Hunan) Co., Ltd (华润置地（湖南）有限公司, a subsidiary of CR Land). Mr. Sun holds a Bachelor's Degree in Engineering from Dalian University of Technology (大连理工大学).
Mr. Sun Yongqiang，was appointed as a non-executive Director and a member of the Remuneration Committee on 27 December 2023. He currently serves as a designated external director of business units of China Resources (Holdings) Company Limited. Mr. Sun joined China Resources Group in March 2001. From 2011 to 2023, he successively served as vice president, chief human resources officer and human resources director of China Resources Land Limited (“CR Land”, which is listed on the Main Board of the Stock Exchange, Stock Code: 1109), and also served as General manager and deputy general manager of China Resources Land (Hunan) Co., Ltd (华润置地（湖南）有限公司, a subsidiary of CR Land). Mr. Sun holds a Bachelor's Degree in Engineering from Dalian University of Technology (大连理工大学).
Guo Chuan - Non-executive Director
Mr. Guo Chuan, has been appointed as a non-executive Director on 7 June 2024. Mr. Guo has joined Beijing State-owned Capital Operation and Management Company Limited (“BSCOMC”) since January 2024, and is currently the deputy party committee secretary, director and general manager of BSCOMC. From 1997 to 2024, he held various positions at Beijing North Star Company Limited (the shares of which are listed on the Main Board of the Stock Exchange of Hong Kong Limited (the “Stock Exchange”) (stock code: 588) and on the Shanghai Stock Exchange (stock code: 601588)), including serving as the director of the secretariat of the board of directors, secretary to the board of directors, chief legal advisor and deputy general manager, and as an executive director from May 2018 to January 2024. Mr. Guo graduated from the Capital University of Economics and Business with a bachelor’s degree in economic law, and the University of International Business and Economics with an EMBA degree, and is a qualified lawyer.
Mr. Guo Chuan, has been appointed as a non-executive Director on 7 June 2024. Mr. Guo has joined Beijing State-owned Capital Operation and Management Company Limited (“BSCOMC”) since January 2024, and is currently the deputy party committee secretary, director and general manager of BSCOMC. From 1997 to 2024, he held various positions at Beijing North Star Company Limited (the shares of which are listed on the Main Board of the Stock Exchange of Hong Kong Limited (the “Stock Exchange”) (stock code: 588) and on the Shanghai Stock Exchange (stock code: 601588)), including serving as the director of the secretariat of the board of directors, secretary to the board of directors, chief legal advisor and deputy general manager, and as an executive director from May 2018 to January 2024. Mr. Guo graduated from the Capital University of Economics and Business with a bachelor’s degree in economic law, and the University of International Business and Economics with an EMBA degree, and is a qualified lawyer.
Jiao Ruifang - Non-executive Director
Mdm. Jiao Ruifang, was appointed as a non-executive Director and a member of the audit committee of the Company in January 2022. Mdm. Jiao joined the BSCOMC in 2014 and is currently the general manager of the capital operation department of the BSCOMC and a non-independent director of Beijing Urban-Rural Commercial (Group) Co., Ltd. (北京城乡商业(集团)股份有限公司) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600861). Mdm. Jiao was appointed as a director of Hainan Jingliang Holdings Co., Ltd. (海南京粮控股股份有限公司) (the shares of which are listed on Shenzhen Stock Exchange, stock code: 000505 and 200505) from March 2022 to September 2022 and Beiqi Foton Motor Co., Ltd. (北汽福田汽车股份有限公司) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600166) from January 2022 to November 2022. Mdm. Jiao served as the board secretary of Beiren Printing Machinery Holdings Limited (北人 印刷机械股份有限公司), the board secretary of Beijing Jingcheng Machinery Machinery Electric Company Limited (北京京城机电股份有限公司) and the deputy general manager of Beijing Tianhai Industrial Co., Ltd. (北京天海工业有限公司). Mdm. Jiao holds an MBA in Finance from The Chinese University of Hong Kong-Tsinghua University.
Mdm. Jiao Ruifang, was appointed as a non-executive Director and a member of the audit committee of the Company in January 2022. Mdm. Jiao joined the BSCOMC in 2014 and is currently the general manager of the capital operation department of the BSCOMC and a non-independent director of Beijing Urban-Rural Commercial (Group) Co., Ltd. (北京城乡商业(集团)股份有限公司) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600861). Mdm. Jiao was appointed as a director of Hainan Jingliang Holdings Co., Ltd. (海南京粮控股股份有限公司) (the shares of which are listed on Shenzhen Stock Exchange, stock code: 000505 and 200505) from March 2022 to September 2022 and Beiqi Foton Motor Co., Ltd. (北汽福田汽车股份有限公司) (the shares of which are listed on the Shanghai Stock Exchange, stock code: 600166) from January 2022 to November 2022. Mdm. Jiao served as the board secretary of Beiren Printing Machinery Holdings Limited (北人 印刷机械股份有限公司), the board secretary of Beijing Jingcheng Machinery Machinery Electric Company Limited (北京京城机电股份有限公司) and the deputy general manager of Beijing Tianhai Industrial Co., Ltd. (北京天海工业有限公司). Mdm. Jiao holds an MBA in Finance from The Chinese University of Hong Kong-Tsinghua University.
Chiu Mun Wai - Independent Non-executive Director
Mdm. Chiu Mun Wai, aged 55. Mdm. Chiu has over 30 years of experience in audit, financing and accounting industries. Mdm. Chiu joined KPMG (Hong Kong) (毕马威会计师 事务所(香港)) in August 1991 and served as a partner of KPMG Huazhen LLP Shenzhen branch (毕马威华振会计师事务所(特殊普通合伙)深圳分所) from July 2005 to March 2018. From August 2018 to December 2019, Mdm. Chiu served as the vice chief financial officer of SCPG Capital Company Limited (印力资本管理有限公司). From April 2011 to March 2017, Mdm. Chiu was also a member of the Appeal Review Committee of the Shenzhen Stock Exchange (深圳证券交易所上诉复核委员会). Mdm. Chiu is currently an independent non-executive director of Bama Tea Co., Ltd. (八马茶业股份有限公司) (a company which has submitted an application for listing to the Stock Exchange) since January 2025. Mdm. Chiu obtained her bachelor’s degree in law from Peking University in the PRC and her master’s degree in science, majoring in finance, from the Chinese University of Hong Kong in 1999. Mdm. Chiu has been a certified public accountant of the Hong Kong Institute of Certified Public Accountants (香港会计师公会注册会计师) since January 1995.
Mdm. Chiu Mun Wai, aged 55. Mdm. Chiu has over 30 years of experience in audit, financing and accounting industries. Mdm. Chiu joined KPMG (Hong Kong) (毕马威会计师 事务所(香港)) in August 1991 and served as a partner of KPMG Huazhen LLP Shenzhen branch (毕马威华振会计师事务所(特殊普通合伙)深圳分所) from July 2005 to March 2018. From August 2018 to December 2019, Mdm. Chiu served as the vice chief financial officer of SCPG Capital Company Limited (印力资本管理有限公司). From April 2011 to March 2017, Mdm. Chiu was also a member of the Appeal Review Committee of the Shenzhen Stock Exchange (深圳证券交易所上诉复核委员会). Mdm. Chiu is currently an independent non-executive director of Bama Tea Co., Ltd. (八马茶业股份有限公司) (a company which has submitted an application for listing to the Stock Exchange) since January 2025. Mdm. Chiu obtained her bachelor’s degree in law from Peking University in the PRC and her master’s degree in science, majoring in finance, from the Chinese University of Hong Kong in 1999. Mdm. Chiu has been a certified public accountant of the Hong Kong Institute of Certified Public Accountants (香港会计师公会注册会计师) since January 1995.
Shi Luwen - Independent Non-executive Director
Mr. Shi Luwen, aged 61, has more than 38 years of experience in medical research. Since July 1987, he has been working at and is currently a professor in pharmaceutical administration and clinical pharmacy at the School of Pharmaceutical Sciences of Peking University (北京大学药学院) (formerly known as School of Pharmaceutical Sciences of Beijing Medical University (北京医科大学药学院)). Since 2002, he has worked as a director at the International Research Center for Medical Administration of Peking University (北京大学医药管理国际研究中心), where he has been primarily involved in research and teaching. From December 2015 to December 2021, Mr. Shi served as an independent director of China Meheco Group Co., Ltd. (中国医药健康产业股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600056)). From May 2017 to July 2020,he served as a director of Zhejiang CONBA Pharmaceutical Co., Ltd (浙江康恩贝制药股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600572)). Mr.Shi has served as an independent non-executive director of Hospital Corporation of ChinaLimited (弘和仁爱医疗集团有限公司) (a company listed on the Stock Exchange (stockcode: 3869)) since December 2016, an independent non-executive director of DragonLaboratory Instruments Limited (大龙兴创实验仪器(北京)股份公司) since June 2020, anindependent non-executive director of Centergate Technologies (Holding) Co., Ltd (北京中关村科技发展(控股)股份有限公司) (a company listed on the Shenzhen Stock Exchange(stock code: 000931)) since February 2022, an independent non-executive director ofShandong Boan Biotechnology Co., Ltd. (山东博安生物技术股份有限公司) (a companylisted on the Stock Exchange (stock code: 6955)) since March 2022, an independent non executive director of China National Medicines Corporation Ltd. (国药集团药业股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600511)) since April 2022, and an independent non-executive director of Sunho Biologics, Inc. (盛禾生物控股有限公司) (a company listed on the Stock Exchange (stock code: 2898)) since July 2023. Mr. Shi obtained his bachelor's degree in chemistry from Beijing Medical University (北京医科大学) in July 1987. He further obtained his master’s degree in education from the University of Illinois at Chicago inIllinois in July 1992. He obtained his independent director qualification from the Shanghai Stock Exchange in January 2016.
Mr. Shi Luwen, aged 61, has more than 38 years of experience in medical research. Since July 1987, he has been working at and is currently a professor in pharmaceutical administration and clinical pharmacy at the School of Pharmaceutical Sciences of Peking University (北京大学药学院) (formerly known as School of Pharmaceutical Sciences of Beijing Medical University (北京医科大学药学院)). Since 2002, he has worked as a director at the International Research Center for Medical Administration of Peking University (北京大学医药管理国际研究中心), where he has been primarily involved in research and teaching. From December 2015 to December 2021, Mr. Shi served as an independent director of China Meheco Group Co., Ltd. (中国医药健康产业股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600056)). From May 2017 to July 2020,he served as a director of Zhejiang CONBA Pharmaceutical Co., Ltd (浙江康恩贝制药股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600572)). Mr.Shi has served as an independent non-executive director of Hospital Corporation of ChinaLimited (弘和仁爱医疗集团有限公司) (a company listed on the Stock Exchange (stockcode: 3869)) since December 2016, an independent non-executive director of DragonLaboratory Instruments Limited (大龙兴创实验仪器(北京)股份公司) since June 2020, anindependent non-executive director of Centergate Technologies (Holding) Co., Ltd (北京中关村科技发展(控股)股份有限公司) (a company listed on the Shenzhen Stock Exchange(stock code: 000931)) since February 2022, an independent non-executive director ofShandong Boan Biotechnology Co., Ltd. (山东博安生物技术股份有限公司) (a companylisted on the Stock Exchange (stock code: 6955)) since March 2022, an independent non executive director of China National Medicines Corporation Ltd. (国药集团药业股份有限公司) (a company listed on the Shanghai Stock Exchange (stock code: 600511)) since April 2022, and an independent non-executive director of Sunho Biologics, Inc. (盛禾生物控股有限公司) (a company listed on the Stock Exchange (stock code: 2898)) since July 2023. Mr. Shi obtained his bachelor's degree in chemistry from Beijing Medical University (北京医科大学) in July 1987. He further obtained his master’s degree in education from the University of Illinois at Chicago inIllinois in July 1992. He obtained his independent director qualification from the Shanghai Stock Exchange in January 2016.
Fu Tingmei - Independent Non-executive Director
Mr. Fu Tingmei, was appointed as an independent non-executive Director and Chairman of Corporate Governance Committee, a member of Remuneration and Appraisal Committee, a member of Nomination Committee and a member of Audit Committee in June 2016. Mr. Fu has over 20 years of experience in investment, finance, law and business management. Mr. Fu currently serves as an independent non-executive director of China Resources Medical Holdings Company Limited (stock code: 1515), Guotai Junan International Holdings Limited, a company listed on the Stock Exchange (stock code: 1788), COFCO Joycome Foods Limited (formerly known as “COFCO Meat Holdings Limited”), a company listed on the Stock Exchange (stock code: 1610) and China Zheshang Bank Co., Ltd. (a company listed on the main board of The Stock Exchange of Hong Kong Limited (stock code: 2016) and the Shanghai Stock Exchange（stock code: 601916). Mr. Fu was an independent non-executive director of Beijing Enterprises Holdings Limited, a company listed on the Stock Exchange (stock code: 0392) from July 2008 to June 2017, an independent non-executive director of CPMC Holdings Limited, a company listed on the Stock Exchange (stock code: 0906) from June 2008 to July 2019 and an independent nonexecutive director of Postal Savings Bank of China Co., Ltd., a company listed on the Stock Exchange (stock code: 1658) from May 2016 to March 2023. Mr. Fu holds a master’s degree in law and a Ph.D. degree in law from London University, the United Kingdom.
Mr. Fu Tingmei, was appointed as an independent non-executive Director and Chairman of Corporate Governance Committee, a member of Remuneration and Appraisal Committee, a member of Nomination Committee and a member of Audit Committee in June 2016. Mr. Fu has over 20 years of experience in investment, finance, law and business management. Mr. Fu currently serves as an independent non-executive director of China Resources Medical Holdings Company Limited (stock code: 1515), Guotai Junan International Holdings Limited, a company listed on the Stock Exchange (stock code: 1788), COFCO Joycome Foods Limited (formerly known as “COFCO Meat Holdings Limited”), a company listed on the Stock Exchange (stock code: 1610) and China Zheshang Bank Co., Ltd. (a company listed on the main board of The Stock Exchange of Hong Kong Limited (stock code: 2016) and the Shanghai Stock Exchange（stock code: 601916). Mr. Fu was an independent non-executive director of Beijing Enterprises Holdings Limited, a company listed on the Stock Exchange (stock code: 0392) from July 2008 to June 2017, an independent non-executive director of CPMC Holdings Limited, a company listed on the Stock Exchange (stock code: 0906) from June 2008 to July 2019 and an independent nonexecutive director of Postal Savings Bank of China Co., Ltd., a company listed on the Stock Exchange (stock code: 1658) from May 2016 to March 2023. Mr. Fu holds a master’s degree in law and a Ph.D. degree in law from London University, the United Kingdom.
Zhang Kejian - Independent Non-executive Director
Mr. Zhang Kejian, was appointed as an independent non-executive Director and a member of Audit Committee, a member of Remuneration and Appraisal Committee, a member of Nomination Committee and a member of Corporate Governance Committee in June 2016. Mr. Zhang also serves as an independent director of Zhejiang Hisoar Pharmaceutical Co., Ltd. (浙江海翔药业股份有限公司) (a company listed on Shenzhen Stock Exchange, stock code: 002099), a non-independent director of 博济医药科技股份有限公司 Boji Medical Technology Co., Ltd. (formerly known as: Guangzhou Boji Medical Biotechnological Co., Ltd. (广州博济医药生物技术股份有限公司)) (a company listed on Shenzhen Stock Exchange GEM, stock code: 300404), an independent director of Liaoning Chengda Biotechnology Co., Ltd. (辽宁成大生物股份有限公司) (a company listed on Shanghai Stock Exchange, stock code: 688739) and the Chief Scientist of The South China Center for Innovative Pharmaceuticals. Mr. Zhang has over 20 years of experience in the pharmaceutical industry of PRC. He was an independent director of CR Double-Crane from February 2016 to June 2018, an independent director of Yifan Pharmaceutical Co., Ltd. (a company listed on Shenzhen Stock Exchange, stock code: 002019) from October 2014 to November 2020 and an independent director of Hunan Fangsheng Pharmaceutical Co., Ltd (a company listed on Shanghai Stock Exchange, stock code: 603998) from October 2018 to January 2021. He was employed as a professor of School of Pharmaceutical Sciences of Sun Yat-sen University and the director (Pharmacy Administration) of The South China Center for Innovative Pharmaceuticals, a researcher at the Institute of Medicine, Chinese Academy of Medical Sciences (中国医学科学院药物研究所), and successively served as a deputy director of Pharmaceutical Evaluation Center (药品审评中心) and a deputy director of Medical Device Evaluation Center (医疗器械技术审评中心) under the State Food and Drug Administration of the PRC (国家食品药品监督管理局). Mr. Zhang received a master’s degree in pathophysiology from China Medical University in Shenyang, the PRC and a doctor’s degree in pharmacy from the School of Pharmaceutical Sciences of Chiba University in Chiba, Japan.
Mr. Zhang Kejian, was appointed as an independent non-executive Director and a member of Audit Committee, a member of Remuneration and Appraisal Committee, a member of Nomination Committee and a member of Corporate Governance Committee in June 2016. Mr. Zhang also serves as an independent director of Zhejiang Hisoar Pharmaceutical Co., Ltd. (浙江海翔药业股份有限公司) (a company listed on Shenzhen Stock Exchange, stock code: 002099), a non-independent director of 博济医药科技股份有限公司 Boji Medical Technology Co., Ltd. (formerly known as: Guangzhou Boji Medical Biotechnological Co., Ltd. (广州博济医药生物技术股份有限公司)) (a company listed on Shenzhen Stock Exchange GEM, stock code: 300404), an independent director of Liaoning Chengda Biotechnology Co., Ltd. (辽宁成大生物股份有限公司) (a company listed on Shanghai Stock Exchange, stock code: 688739) and the Chief Scientist of The South China Center for Innovative Pharmaceuticals. Mr. Zhang has over 20 years of experience in the pharmaceutical industry of PRC. He was an independent director of CR Double-Crane from February 2016 to June 2018, an independent director of Yifan Pharmaceutical Co., Ltd. (a company listed on Shenzhen Stock Exchange, stock code: 002019) from October 2014 to November 2020 and an independent director of Hunan Fangsheng Pharmaceutical Co., Ltd (a company listed on Shanghai Stock Exchange, stock code: 603998) from October 2018 to January 2021. He was employed as a professor of School of Pharmaceutical Sciences of Sun Yat-sen University and the director (Pharmacy Administration) of The South China Center for Innovative Pharmaceuticals, a researcher at the Institute of Medicine, Chinese Academy of Medical Sciences (中国医学科学院药物研究所), and successively served as a deputy director of Pharmaceutical Evaluation Center (药品审评中心) and a deputy director of Medical Device Evaluation Center (医疗器械技术审评中心) under the State Food and Drug Administration of the PRC (国家食品药品监督管理局). Mr. Zhang received a master’s degree in pathophysiology from China Medical University in Shenyang, the PRC and a doctor’s degree in pharmacy from the School of Pharmaceutical Sciences of Chiba University in Chiba, Japan.
